Health & Environmental Research Online (HERO)


Print Feedback Export to File
3749289 
Journal Article 
Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats 
Kim, SJ; Heo, SH; Lee, DS; Hwang, IG; Lee, YB; Cho, HY 
2016 
Yes 
Food and Chemical Toxicology
ISSN: 0278-6915
EISSN: 1873-6351 
Elsevier 
97 
Elsevier 
243-255 
English 
The aim of this study was to confirm and investigate the gender differences in pharmacokinetic (PK) characteristics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances (PFASs) consisted of perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) in both male and female rats. For this study, a simultaneous determination method of the 3 PFASs in rat plasma and tissues was developed and validated using a UPLC-MS/MS system. The PK parameters after a single oral or intravenous administration of the 3 PFASs in both rats were calculated using WinNonlin(®) software. The mean half-life of the 3 PFASs in female and male rats was in the range of 0.15-0.19 and 1.6-1.8 days for PFOA, 23.5-24.8 and 26.4-28.7 days for PFOS, and 0.9-1.7 and 20.7-26.9 days for PFHxS, respectively. The 3 PFASs were highly distributed in the liver and kidney. These results suggest that there are gender differences in the PKs for PFOA and PFHxS in rats, whereas the PFOS represented no significant gender differences except the Kp value of liver. The validated simultaneous determination method of the 3 PFASs was also within the accepted criteria of the international guidance. 
PFOA; PFOS; PFHxS; Gender difference; Pharmacokinetics; Tissue distribution 
PFAS
• Additional PFAS (formerly XAgency)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Web of Science
     Not prioritized for screening
     Perfluorooctane
     Potassium perfluorooctanoate
     Sodium perfluorooctanoate
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               Pubmed
               WOS
     PFHxS (355-46-4)
          Literature search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
     Not prioritized for screening
     Ammonium perfluorooctanoate
     Perfluorinated compounds
     Perfluorohexanesulfonic acid
     Perfluorooctane
     Perfluorooctanesulfonic acid
     Perfluorooctanoic acid
• PFHxA
     HAWC
• PFHxS
     Database searches
          Pubmed
          Toxline
          WOS
          Scopus
     Inclusion
          TiAb
     Supplemental
          Full Text
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          Pubmed
          WOS
     Screening Results
          Toxicokinetic studies
               ADME
          Susceptible populations
     Literature Search Update (2013-2019)
          PubMed
          WOS
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers
• Yale PFAS Liver study